Randomized phase II study of AKT blockade with ipatasertib (GDC-0068) and abiraterone (Abi) vs. Abi alone in patients with metastatic castration-resistant prostate cancer (mCRPC) after docetaxel chemotherapy (A. MARTIN Study).

2016 ◽  
Vol 34 (15_suppl) ◽  
pp. 5017-5017 ◽  
Author(s):  
Johann S. De Bono ◽  
Ugo De Giorgi ◽  
Christophe Massard ◽  
Sergio Bracarda ◽  
Ivo Kocak ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Phase Ii ◽  
Phase Ii Study ◽  
Castration Resistant Prostate Cancer ◽  
Castration Resistant ◽  
Randomized Phase Ii ◽  
Docetaxel Chemotherapy

Randomized phase II study of nintedanib in metastatic castration-resistant prostate cancer postdocetaxel

2014 ◽  
Vol 25 (9) ◽  
pp. 1081-1088 ◽  
Author(s):  
Jean-Pierre Droz ◽  
Jaques Medioni ◽  
Christine Chevreau ◽  
Helene De Mont-Serrat ◽  
Michael Merger ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Phase Ii ◽  
Phase Ii Study ◽  
Castration Resistant Prostate Cancer ◽  
Castration Resistant ◽  
Randomized Phase Ii

scholarly journals A randomized phase II study of pelareorep and docetaxel or docetaxel alone in men with metastatic castration resistant prostate cancer: CCTG study IND 209

Oncotarget ◽  
2018 ◽  
Vol 9 (8) ◽  
pp. 8155-8164 ◽  
Author(s):  
Bernhard Josef Eigl ◽  
Kim Chi ◽  
Dongsheng Tu ◽  
Sebastien J. Hotte ◽  
Eric Winquist ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Phase Ii ◽  
Phase Ii Study ◽  
Castration Resistant Prostate Cancer ◽  
Castration Resistant ◽  
Randomized Phase Ii
Sign in / Sign up

Export Citation Format

Share Document